A Double-Blind, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Tolerability of MK0663/Etoricoxib in the Treatment of Pain After Abdominal Hysterectomy

NCT00788710 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.

Details

Lead sponsor	Organon and Co
Phase	Phase 3
Status	COMPLETED
Enrolment	430
Start date	2008-10
Completion	2010-07

Conditions

• Acute Pain Following a Total Abdominal Hysterectomy

Interventions

• etoricoxib (MK0663) 120 mg
• Comparator: Placebo
• etoricoxib (MK0663) 90 mg

Primary outcomes

• Average Pain Intensity at Rest Over Days 1 to 3 — 3 Days
  Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.